Active substance
Desipramine
- US FDA 18
- Health Canada 5
- US price lines 6
- Safety 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| DESIPRAMINE HYDROCHLORIDE | 50MG | tablet · oral | ACTAVIS TOTOWA | Prescription | 5 Jun 1987 |
| DESIPRAMINE HYDROCHLORIDE | 25MG | tablet · oral | ACTAVIS TOTOWA | Prescription | 5 Jun 1987 |
| DESIPRAMINE HYDROCHLORIDE | 75MG | tablet · oral | ACTAVIS TOTOWA | Prescription | 5 Oct 1987 |
| DESIPRAMINE HYDROCHLORIDE | 100MG | tablet · oral | ACTAVIS TOTOWA | Prescription | 5 Oct 1987 |
| DESIPRAMINE HYDROCHLORIDE | 100MG; 10MG; 25MG; 50MG; 75MG; 150MG | tablet · oral | CHARTWELL RX | Prescription | 20 Jun 1988 |
| DESIPRAMINE HYDROCHLORIDE | 10MG; 150MG | tablet · oral | ACTAVIS TOTOWA | Prescription | 9 Feb 1996 |
| DESIPRAMINE HYDROCHLORIDE | 10MG; 25MG; 50MG; 75MG; 100MG; 150MG | tablet · oral | INGENUS PHARMS LLC | Prescription | 26 Dec 2017 |
| DESIPRAMINE HYDROCHLORIDE | 10MG; 25MG; 50MG; 75MG; 100MG; 150MG | tablet · oral | ALEMBIC | Prescription | 7 Jul 2021 |
| NORPRAMIN | 25MG; 50MG; 75MG; 100MG; 150MG; 10MG | tablet · oral | VALIDUS PHARMS | Discontinued | 20 Nov 1964 |
| PERTOFRANE | 25MG; 50MG | capsule · oral | SANOFI AVENTIS US | Discontinued | 10 Apr 1968 |
| DESIPRAMINE HYDROCHLORIDE | 100MG; 25MG; 50MG; 75MG; 150MG | tablet · oral | ANI PHARMS | Discontinued | 29 May 1997 |
| DESIPRAMINE HYDROCHLORIDE | 10MG; 25MG; 50MG; 75MG; 100MG; 150MG | tablet · oral | AMNEAL PHARMS CO | Discontinued | 17 Mar 2016 |
| DESIPRAMINE HYDROCHLORIDE | 10MG; 25MG; 50MG; 75MG; 100MG; 150MG | tablet · oral | HERITAGE | Discontinued | 5 May 2016 |
| DESIPRAMINE HYDROCHLORIDE | 10MG; 25MG; 50MG; 75MG; 100MG; 150MG | tablet · oral | ANI PHARMS | Discontinued | 28 Oct 2016 |
| DESIPRAMINE HYDROCHLORIDE | 25MG | tablet · oral | USL PHARMA | Discontinued | |
| DESIPRAMINE HYDROCHLORIDE | 50MG | tablet · oral | USL PHARMA | Discontinued | |
| DESIPRAMINE HYDROCHLORIDE | 75MG | tablet · oral | USL PHARMA | Discontinued | |
| DESIPRAMINE HYDROCHLORIDE | 100MG | tablet · oral | USL PHARMA | Discontinued |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| DESIPRAMINE | 02216248 | 10 MG | TABLET · ORAL | AA PHARMA INC |
| DESIPRAMINE | 02216256 | 25 MG | TABLET · ORAL | AA PHARMA INC |
| DESIPRAMINE | 02216264 | 50 MG | TABLET · ORAL | AA PHARMA INC |
| DESIPRAMINE | 02216272 | 75 MG | TABLET · ORAL | AA PHARMA INC |
| DESIPRAMINE | 02216280 | 100 MG | TABLET · ORAL | AA PHARMA INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | DESIPRAMINE 10 MG TABLET | $0.13641 | per EA | 23 Sep 2026 |
| US NADAC | DESIPRAMINE 100 MG TABLET | $0.44611 | per EA | 23 Sep 2026 |
| US NADAC | DESIPRAMINE 150 MG TABLET | $0.83165 | per EA | 23 Sep 2026 |
| US NADAC | DESIPRAMINE 25 MG TABLET | $0.12692 | per EA | 23 Sep 2026 |
| US NADAC | DESIPRAMINE 50 MG TABLET | $0.21766 | per EA | 23 Sep 2026 |
| US NADAC | DESIPRAMINE 75 MG TABLET | $0.27565 | per EA | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 24 Jun 2025 NORPRAMIN — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.